Savara (SVRA) Short-Term Debt issuances (2016 - 2017)
Savara's (SVRA) quarterly Short-Term Debt issuances came in at -$3.6 million in Q4 2017, down 134.43% year-on-year from $10.4 million in Q4 2016, and down 124.56% on a QoQ basis from $14.5 million in Q2 2017.
Savara (SVRA) Short-Term Debt issuances (2016 - 2017) Analysis & Trends
Savara (SVRA) has 2 years of Short-Term Debt issuances data on file, last reported at -$3.6 million in Q4 2017.
- On a quarterly basis, Short-Term Debt issuances fell 134.43% year-over-year to -$3.6 million in Q4 2017; TTM through Dec 2017 was $11.3 million, a N/A change from a year earlier, with the FY2018 full-year figure at $9.4 million, down 17.32% from the prior year.
- Short-Term Debt issuances for Q4 2017 stood at -$3.6 million, down from $14.5 million in the prior quarter.
- Over the last five years, Short-Term Debt issuances for SVRA reached as high as $14.5 million in Q2 2017 and fell as low as -$3.6 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 58.20 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -3.57 Mn |
| Dec 31, 2017 | -3.57 Mn |
| Jun 30, 2017 | 14.53 Mn |
| Jun 30, 2017 | 14.53 Mn |
| Mar 31, 2017 | 368,000.00 |
| Mar 31, 2017 | 368,000.00 |
| Dec 31, 2016 | 10.36 Mn |
| Dec 31, 2016 | 10.36 Mn |